Glomerulonephritis-Pipeline Review, H1 2016

Glomerulonephritis-Pipeline Review, H1 2016

  • Products Id :- GMDHC7724IDB
  • |
  • Pages: 136
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Glomerulonephritis-Pipeline Review, H1 2016', provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis

The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects

The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Glomerulonephritis Overview 9

Therapeutics Development 10

Pipeline Products for Glomerulonephritis-Overview 10

Pipeline Products for Glomerulonephritis-Comparative Analysis 11

Glomerulonephritis-Therapeutics under Development by Companies 12

Glomerulonephritis-Therapeutics under Investigation by Universities/Institutes 14

Glomerulonephritis-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Glomerulonephritis-Products under Development by Companies 18

Glomerulonephritis-Products under Investigation by Universities/Institutes 20

Glomerulonephritis-Companies Involved in Therapeutics Development 21

Alexion Pharmaceuticals, Inc. 21

Amyndas Pharmaceuticals LLC 22

Anthera Pharmaceuticals Inc. 23

Avexxin AS 24

Biogen, Inc. 25

Complexa, Inc. 26

Dimerix Bioscience Pty Ltd 27

Escala Therapeutics, Inc. 28

FibroStatin SL 29

GlaxoSmithKline Plc 30

Mallinckrodt Plc 31

Merck KGaA 32

Omeros Corporation 33

Pfizer Inc. 34

Pharmalink AB 35

Retrophin Inc. 36

Rigel Pharmaceuticals, Inc. 37

Shire Plc 38

Toray Industries, Inc. 39

Variant Pharmaceuticals, Inc. 40

Glomerulonephritis-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

(irbesartan + propagermanium)-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AMY-101-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AVX-235-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

belimumab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

blisibimod-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

budesonide-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

cilengitide-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

corticotropin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

CXA-10-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

DEXM-74-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Drug to Inhibit GPBP for Glomerulonephritis and Cancer-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Drug to Target Mac-1 for Vasculitis and Glomerulonephritis-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

eculizumab-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

fostamatinib disodium-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

losmapimod-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

OMS-721-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

PBF-1472-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

PF-1355-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Recombinant Enzyme for Immunoglobulin A Nephropathy-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

rituximab-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SHP-627-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

sparsentan-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Stem Cell Therapy for IgA Nephropathy-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Vaccine to Target CD40 for Membranous Glomerulonephritis-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

VAR-200-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Glomerulonephritis-Recent Pipeline Updates 101

Glomerulonephritis-Dormant Projects 127

Glomerulonephritis-Discontinued Products 128

Glomerulonephritis-Product Development Milestones 129

Featured News & Press Releases 129

Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 129

Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 130

Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 130

Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 131

Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 131

Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 132

Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 133

Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 133

Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 134

Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 134

Appendix 135

Methodology 135

Coverage 135

Secondary Research 135

Primary Research 135

Expert Panel Validation 135

Contact Us 135

Disclaimer 136

List of Figures

Number of Products under Development for Glomerulonephritis, H1 2016 10

Number of Products under Development for Glomerulonephritis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Products, H1 2016 17

Assessment by Monotherapy Products, H1 2016 41

Number of Products by Top 10 Targets, H1 2016 43

Number of Products by Stage and Top 10 Targets, H1 2016 43

Number of Products by Top 10 Mechanism of Actions, H1 2016 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45

Number of Products by Routes of Administration, H1 2016 47

Number of Products by Stage and Routes of Administration, H1 2016 47

Number of Products by Molecule Types, H1 2016 49

Number of Products by Stage and Molecule Types, H1 2016 49

List of Tables

Number of Products under Development for Glomerulonephritis, H1 2016 10

Number of Products under Development for Glomerulonephritis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 13

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Development, H1 2016 17

Products under Development by Companies, H1 2016 18

Products under Development by Companies, H1 2016 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2016 20

Glomerulonephritis-Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 21

Glomerulonephritis-Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 22

Glomerulonephritis-Pipeline by Anthera Pharmaceuticals Inc., H1 2016 23

Glomerulonephritis-Pipeline by Avexxin AS, H1 2016 24

Glomerulonephritis-Pipeline by Biogen, Inc., H1 2016 25

Glomerulonephritis-Pipeline by Complexa, Inc., H1 2016 26

Glomerulonephritis-Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 27

Glomerulonephritis-Pipeline by Escala Therapeutics, Inc. , H1 2016 28

Glomerulonephritis-Pipeline by FibroStatin SL, H1 2016 29

Glomerulonephritis-Pipeline by GlaxoSmithKline Plc, H1 2016 30

Glomerulonephritis-Pipeline by Mallinckrodt Plc, H1 2016 31

Glomerulonephritis-Pipeline by Merck KGaA, H1 2016 32

Glomerulonephritis-Pipeline by Omeros Corporation, H1 2016 33

Glomerulonephritis-Pipeline by Pfizer Inc., H1 2016 34

Glomerulonephritis-Pipeline by Pharmalink AB, H1 2016 35

Glomerulonephritis-Pipeline by Retrophin Inc., H1 2016 36

Glomerulonephritis-Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 37

Glomerulonephritis-Pipeline by Shire Plc, H1 2016 38

Glomerulonephritis-Pipeline by Toray Industries, Inc., H1 2016 39

Glomerulonephritis-Pipeline by Variant Pharmaceuticals, Inc., H1 2016 40

Assessment by Monotherapy Products, H1 2016 41

Assessment by Combination Products, H1 2016 42

Number of Products by Stage and Target, H1 2016 44

Number of Products by Stage and Mechanism of Action, H1 2016 46

Number of Products by Stage and Route of Administration, H1 2016 48

Number of Products by Stage and Molecule Type, H1 2016 50

Glomerulonephritis Therapeutics-Recent Pipeline Updates, H1 2016 101

Glomerulonephritis-Dormant Projects, H1 2016 127

Glomerulonephritis-Discontinued Products, H1 2016 128

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Alexion Pharmaceuticals, Inc. Amyndas Pharmaceuticals LLC Anthera Pharmaceuticals Inc. Avexxin AS Biogen, Inc. Complexa, Inc. Dimerix Bioscience Pty Ltd Escala Therapeutics, Inc. FibroStatin SL GlaxoSmithKline Plc Mallinckrodt Plc Merck KGaA Omeros Corporation Pfizer Inc. Pharmalink AB Retrophin Inc. Rigel Pharmaceuticals, Inc. Shire Plc Toray Industries, Inc. Variant Pharmaceuticals, Inc.

Glomerulonephritis Therapeutic Products under Development, Key Players in Glomerulonephritis Therapeutics, Glomerulonephritis Pipeline Overview, Glomerulonephritis Pipeline, Glomerulonephritis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520



I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]